

HETEROCYCLES, Vol. 76, No. 2, 2008, pp. 1497 - 1509. © The Japan Institute of Heterocyclic Chemistry
Received, 8th May, 2008, Accepted, 9th June, 2008, Published online, 12th June, 2008. COM-08-S(N)114

**SYNTHESIS OF TETRAHYDROISOQUINOLINE ANTITUMOR
NATURAL PRODUCTS: CONSTRUCTION OF TRICYCLIC LACTAMS
THROUGH PICTET-SPENGLER-TYPE CYCLIZATION OF
N-METHYL-3-ARYLMETHYLPIPERAZINE-2,5-DIONE WITH ETHYL
DIETHOXYACETATE**

Masashi Yokoya, Osamu Kawachi, and Naoki Saito*

Graduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University,
2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan; Tel & Fax:
+81-(0)42-495-8794

E-mail: naoki@my-pharm.ac.jp

Abstract – 6-Hydroxymethyl-7,8,10-trimethoxy-2,6-dimethyl-3,6,11,11a-tetrahydro-2H-pyrazino[1,2-b]isoquinoline-1,4-dione (**10**) was prepared stereoselectively by Pictet-Spengler-type cyclization of the *O,N*-acetal of 3-arylmethylpiperazine-2,5-dione (**8**) in high yield. This procedure provides an efficient route for the total synthesis of renieramycin G and cribrostatin 4.

This paper is dedicated to Professor Ryoji Noyori (2001 Nobel Laureate in Chemistry) on the occasion of his 70th birthday.

INTRODUCTION

The tetrahydroisoquinoline family of natural products, including renieramycins, saframycins, and ecteinascidins, has elicited much excitement both for their novel structures and meager availability in nature, and for their unique mechanisms of action (Figure 1).¹ Although the detailed molecular mechanism of action remains unclear, it has been speculated that the hydroxyl or cyano substituent at C21 position is essential, suggesting that the elimination of the functional group at this position leads to the formation of a potent, electrophilic iminium ion species that has been implicated in the formation of covalent bonds with DNA.² Previous studies have ignited in the structures of renieramycin G (**4**)³ and cribrostatin 4 (**5**),⁴ because both natural products maintained cytotoxicity despite lack of the hemiaminal

or aminonitrile function at C21 (Figure 2). In 2005, Magnus and Matthews^{5a} and Williams and co-workers^{5b} independently accomplished the first total synthesis of (-)-renieramycin G (**4**). The first total synthesis of cribrostatin 4 (**5**) was achieved by Danishefsky and co-workers also in 2005,^{6a} and two years later, Vincent and Williams^{6b} and Chen and Zhu^{6c} completed two total syntheses. However, structure-activity relationship (SAR) studies remain relatively few, because most studies have focused on the total synthesis.




Figure 1. Structures of tetrahydroisoquinoline antitumor natural products

We are very interested in the efficient synthesis of 3,6,11,11a-tetrahydro-2*H*-pyrazino-[1,2-*b*]isoquinoline-1,4-diones (**A**)⁷ for the preparation of various derivatives, along with the total synthesis of renieramycin G (**4**). In this paper, we report recent progress in the construction of the ABC ring core from 3-arylpiperazine-2,5-dione derivative (**6**).⁸




Figure 2. Structures of renieramycin G and cribrostatin 4 along with our target (**A**).

RESULTS AND DISCUSSION

Except for a few examples, it was generally difficult to construct the tetrahydroisoquinoline core with the Pictet-Spengler cyclization of non-basic nitrogen of the secondary amide that could not react with aldehyde to produce an iminium ion species. Thus, all successful total syntheses of **4** and **5** employed the same strategy that included coupling of the tetrahydroisoquinoline core (AB ring core) with amino acid derivatives to afford tertiary amide (Figure 3).^{5,6}




Figure 3. Strategy for the total synthesis of renieramycin G and cribrostatin 4

Treatment of compound **6** with paraformaldehyde in acetic acid and trifluoroacetic acid (TFA) (1:4 v/v) under reflux for 1 h gave **7a** in 85% yield according to the procedure of Ong et al. (Table 1, entry 1).^{9a,b} The reaction of **6** with acetaldehyde under similar conditions for 6 h afforded **7b** in 54% yield as a single isomer. The *trans* stereochemical assignment between C1 and C3 protons was based on nuclear Overhauser enhancement (NOE) between the C-1 methyl protons (δ 1.47) and the proton at C3 (δ 4.35). The structure of compound **7b** was subsequently confirmed by single-crystal X-ray analysis (Figure 4). The stereochemical course of this reaction is rationalized to proceed through (*E*)-iminium isomer. Thus, this cyclization would proceed from the less hindered α -face.





Figure 4. X-Ray structure of compound **7b**

The next step of the investigation was to establish a method for the preparation of a tricyclic compound having a hydroxymethyl or an aminomethyl functionality at C1. The transformation of **6** with ethyl glyoxylate was carried out under similar conditions for 4 h, but only a trace amount of product **7c** (2%) was obtained and 82% of the starting material was recovered. Numerous efforts to improve the yield of product **7c** under several conditions were also unsuccessful (Table 1, entries 3 and 4).^{10,11}




Entry	Aldehyde	Time (h)	Temp (°C)	Product (%)	Recovery of 6 (%)	
1	(CH ₂ O) _n	1	75	7a (R = H)	85	0
2	MeCHO	6	75	7b (R = Me)	54	0
3	CHOCO ₂ Et	4	75	7c (R = CO ₂ Et)	2	82
4	CHOCO ₂ Et	48	75	7c (R = CO ₂ Et)	6	0
5	CHOCO ₂ Et	120	100	7c (R = CO ₂ Et)	8	0

Table 1

This problem was solved with the procedure of Avendaño and co-workers.¹² Treatment of **6** with ethyl 2-chloro-2-ethoxy acetate in the presence of sodium hydride in DMF at 0°C for 2.5 h afforded *N*-alkyl compound **8** (71%) as an inseparable mixture of diastereomers (3:2) along with recovered **6** (12%). It is well known that trimethylsilyl triflate catalyzes effectively the aldol-type *N*-alkylation of lactam through *O*-trimethylsilyllactims. Thus, the reaction of **6** with trimethylsilyl chloride in the presence of triethylamine in dichloromethane gave the *O*-trimethylsilyllactim intermediate. Subsequent treatment with ethyl diethoxyacetate in the presence of trimethylsilyl trifluoromethanesulfonate (TMSOTf) afforded **8** as an inseparable mixture of diastereoisomers (3:2) in 80% yield (Scheme 1). Treatment of **8** in TFA at 70°C for 5 h afforded desired product **7c** (24%); however, the main product was spiro compound **9**¹³ that was obtained in 32% yield as a single isomer, and restored **6** in 35% yield. After extensive investigation of the reaction conditions, the following procedure was found to be optimum in terms of product yield and reproducibility of the reaction. Treatment of **8** with 1.2 equiv. of *p*-toluenesulfonic acid in ClCH₂CH₂Cl under reflux for 36 h gave **7c** in 93% yield (Table 2). Furthermore, the conversion of **6** into **7c** in a one-pot procedure was performed by acid-catalyzed cyclization *via* **8** with TMSOTf in 93% yield.

X-Ray crystallographic analysis of **7c** proved that the stereochemistry was *trans* between C1 and C3 protons (Figure 5). Thus, this stereoselective cyclization would also proceed from the less hindered α -face to the (*E*)-iminium isomer.

In the next step of the investigation, we were able to establish that the chemoselective reduction of the ester carbonyl of **7c** gave hydroxymethyl compound **10** (Scheme 2). Reduction of **7c** with DIBAL in toluene at -78°C was unsuccessful, and only polar polymeric material was produced.¹⁴ In contrast, reduction of **7c** with LiBH_4 in the presence of an equimolar amount of MeOH in THF at 50°C promoted the ester reduction;^{11a,15} however, reduction of one of the lactam carbonyls also proceeded to generate an inseparable mixture of products. Accordingly, the sequence of reactions in Scheme 2 was studied. Hydrolysis of the ester group of **7c** with 10% aqueous NaOH in EtOH afforded desired carboxylic acids in 65% yield as a 1:1 diastereomeric mixture. Alternatively, hydrolysis with LiOH in THF, MeOH, and H_2O afforded a 5:1 mixture of diastereomers. According to Kakinuma and co-workers,¹⁶ the major isomer was treated with ethyl chloroformate and triethylamine in THF to give a mixed anhydride, which was reduced with sodium borohydride in aqueous THF solution to furnish alcohols **10** and **11** in 52% and 17% overall yields, respectively. The stereochemistry of both compounds could not be determined because no information could be acquired from NOE experiments. Thus, major product **10** was transformed into the corresponding 1-methyl compound. Alcohol **10** was treated with $(\text{PhO})_3\text{P}^+\text{CH}_3\text{I}^-$ in DMF to give alkyl iodide **12** in 87% yield.¹⁷ This compound was then hydrogenated with Pd/C to afford **7a** in quantitative yield. This product was identical with the authentic one as described above. Thus, we conclude that the relative stereochemistry of major alcohol **7b** might be *trans* between C1 proton and C3a proton.



Scheme 2

In summary, 6-substituted 7,8,10-trimethoxy-2,6-dimethyl-3,6,11,11a-tetrahydro-2*H*-pyrazino[1,2-*b*]-isoquinoline-1,4-diones were prepared stereoselectively by Pictet-Spengler-type cyclization of *O,N*-acetal of 3-arylmethylpiperazine-2,5-dione in high yields. Efforts to investigate the isomerization from *trans* to *cis* and its application to the total synthesis of renieramycins are under way.

EXPERIMENTAL

All melting points were determined with a Yanagimoto micromelting point apparatus and are uncorrected. IR spectra were obtained with a Shimadzu IRAffinity-1 Fourier Transform Infrared Spectrometer. ¹H-NMR spectra were recorded at 300 MHz on a JEOL-AL-300 spectrometer and at 400 MHz on a JEOL-AL-400 spectrometer. ¹³C-NMR was recorded at 100 MHz (multiplicity determined from distortionless enhancement by polarization transfer (DEPT) spectra). NMR spectra were measured in CDCl₃, and chemical shifts were recorded in δ_H values relative to (CH₃)₄Si as the internal standard. Mass spectra were recorded on a JMS-700 instrument with a direct inlet system operating at 70 eV. Elemental analyses were conducted on a YANACO MT-6 CHN CORDER elemental analyzer.

7,8,10-Trimethoxy-2,9-dimethyl-3,6,11,11a-tetrahydro-2*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione (7a, entry 1) Paraformaldehyde (120.0 mg, 1.00 mmol) was added to a solution of compound **6** (131.4 mg, 0.40 mmol) in acetic acid and TFA (1:4, v/v, 3 mL), and this mixture was heated at 75°C for 1 h. The reaction mixture was poured into water (80 mL) and extracted with CHCl₃ (80 mL x 3). The combined extracts were washed with 5% aqueous NaHCO₃ (80 mL), dried, and concentrated *in vacuo* and the residue was subjected to chromatography on silica gel with CH₂Cl-MeOH (80:1) to give **7a**, which was recrystallized from EtOAc-*n*-hexane to give **7a** (113.1 mg, 85%) as colorless prisms.

mp 145-146°C. IR_{vmax} (KBr) 2932, 1656 cm⁻¹. δ_H 2.19 (3H, s, Ar-CH₃), 2.72 (1H, dd, *J* = 16.4, 12.1 Hz, C11-H), 3.04 (3H, s, *N*-CH₃), 3.57 (1H, dd, *J* = 16.4, 3.7 Hz, C11-H), 3.67 (3H, s, OCH₃), 3.80 (3H, s, OCH₃), 3.86 (3H, s, OCH₃), 4.06 (2H, s, C3-H x 2), 4.12 (1H, dd, *J* = 12.1, 3.7 Hz, C11a-H), 4.12 (1H, d, *J* = 17.4 Hz, C6-H), 5.41 (1H, d, *J* = 17.4 Hz, C6-H). δ_C 9.3 (q, Ar-CH₃), 28.6 (t, C11), 33.4 (q, *N*-CH₃), 40.2 (t, C6), 51.4 (t, C3), 55.4 (d, C11a), 60.1 (q, Ar-OCH₃ x 2), 60.2 (q, Ar-OCH₃), 121.5 (s), 123.2 (s), 124.1 (s), 145.8 (s), 150.2 (s), 152.2 (s), 161.8 (s), 165.1 (s). EI-MS *m/z* (%): 335 (M⁺ + 1, 19), 334 (M⁺, 100), 319 (20), 193 (14). Anal. Calcd for C₁₇H₂₂N₂O₅: C, 61.07; H, 6.63; N, 8.38. Found: C, 60.99; H, 6.77; N, 8.35.

(6*S**, 11a*R**)-7,8,10-Trimethoxy-2,6,9-trimethyl-3,6,11,11a-tetrahydro-2*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione (7b, entry 2) Acetaldehyde (230.0 mg, 4.00 mmol) was added to a solution of compound **6** (131.4 mg, 0.40 mmol) in acetic acid and TFA (1:4, v/v, 3 mL), and this mixture was heated at 75°C for 6 h. The reaction mixture was poured into water (40 mL) and extracted with CHCl₃ (40 mL x 3). The

combined extracts were washed with 5% aqueous NaHCO₃ (40 mL), dried, and concentrated *in vacuo* and the residue was subjected to chromatography on silica gel with CH₂Cl₂-MeOH (100:1) to give **7b**, which was recrystallized from EtOAc-*n*-hexane to give **7b** (111.4 mg, 80%) as yellow prisms.

mp 140-141°C. IR_{vmax} (KBr) 2932, 1666 cm⁻¹. δ_H 1.47 (3H, d, *J* = 7.0 Hz, C12-H), 2.18 (3H, s, Ar-CH₃), 2.71 (1H, dd, *J* = 16.8, 12.5 Hz, C11-H), 3.04 (3H, s, *N*-CH₃), 3.49 (1H, dd, *J* = 16.8, 4.1 Hz, C11-H), 3.67 (3H, s, OCH₃), 3.79 (3H, s, OCH₃), 3.88 (3H, s, OCH₃), 3.99 (1H, d, *J* = 17.5 Hz, C3-H), 4.07 (1H, d, *J* = 17.5 Hz, C3-H), 4.35 (1H, dd, *J* = 12.5, 4.1 Hz, C11a-H), 5.85 (1H, q, *J* = 7.0 Hz, C6-H). δ_C 9.27 (q, Ar-CH₃), 19.7 (q, C12), 28.7 (t, C11), 33.4 (q, *N*-CH₃), 44.9 (d, C6), 51.1 (t, C3), 51.4 (d, C11a), 55.4 (q × 2, Ar-OCH₃), 60.2 (q, Ar-OCH₃), 120.7 (s), 124.3 (s), 128.5 (s), 145.9 (s), 150.4 (s), 152.1 (s), 160.8 (s), 165.5 (s). EI-MS *m/z* (%): 349 (M⁺ + 1, 11), 348 (M⁺, 52), 334 (19), 333 (100), 305 (12), 234 (10). Anal. Calcd for C₁₈H₂₄N₂O₅: C, 62.05; H, 6.94; N, 8.04. Found: C, 62.07; H, 7.12; N, 8.04.

X-Ray crystallographic analysis of 7b All measurements were performed on a Rigaku AFC7S diffractometer with graphite-monochromated CuKα radiation (λ=1.54178 Å). Crystal data: Colorless prismatic crystal, monoclinic, C₁₈H₂₄N₂O₅ (*M*_r=348.40), space group C2/c with *a*=15.562(2) Å, *b*=13.914(2) Å, *c*=32.244(4) Å, β=91.730(10)°, *V*=7197(1) Å³, *Z*=16, and *D*_{calcd}=1.286 g/cm³. The structure was solved by direct methods (SHELXS-97¹⁸) and expanded using Fourier techniques (DIRDIF94¹⁹). Non-hydrogen atoms were refined anisotropically. Hydrogen atoms were included in calculated positions but were not refined. The final cycle of full-matrix least-squares refinement was based on 6486 unique reflections (2θ<135.98°) and 451 variable parameters and converged with unweighted and weighted agreement factors of *R*=0.096, *R*_w=0.197, and *R*₁=0.047 for *I* > 2.0σ(*I*) data. CCDC-No. 687,437 contains supplementary crystallographic data for this paper. These data can be obtained free of charge *via* www.ccdc.cam.ac.uk/data_request/cif.

(6S*, 11aR*)-Ethyl 7,8,10-trimethoxy-2,9-dimethyl-3,6,11,11a-2H-pyrazino[1,2-*b*]-isoquinoline-1,4-dione-6-carboxylate (7b, entry 4) Ethyl glyoxylate (204.0 mg, 2.00 mmol) was added to a solution of compound **6** (64.4 mg, 0.20 mmol) in acetic acid and TFA (1:4, v/v, 2 mL), and this mixture was heated at 75°C for 48 h. The reaction mixture was poured into water (10 mL) and extracted with CHCl₃ (30 mL × 3). The combined extracts were washed with 5% aqueous NaHCO₃ (20 mL), dried, and concentrated *in vacuo* and the residue was subjected to chromatography on silica gel with CH₂Cl₂-MeOH (120:1) to give **7c** (5.0 mg, 6%) as a pale yellow syrup.

Ethyl 2-ethoxy-2-[4-methyl-3,6-dioxo-2-[(2,4,5-trimethoxy-3-methylphenyl)methyl]piperazin-1-yl]-acetate (8) Trimethylsilyl chloride (26.0 μL, 0.20 mmol) was added to a solution of **6** (32.8 mg, 0.10 mmol) with triethylamine (28.4 μL, 0.20 mmol) in CH₂Cl₂ (1 mL) and this reaction mixture was stirred at rt for 2 h. A solution of ethyl diethoxyacetate (36.4 μL, 0.20 mmol) in dry CH₂Cl₂ (1 mL),

followed by TMSOTf (184.4 μ L, 1.02 mmol), was added dropwise respectively over 5 min, and the reaction mixture was stirred at rt for 16 h. The reaction mixture was diluted with 10% aqueous NaHCO₃ (10 mL) and extracted with CHCl₃ (20 mL x 3). The combined extracts were washed with water (20 mL), dried, and concentrated *in vacuo*, and the residue was subjected to chromatography on silica gel with CHCl₃ to give **8** (37.0 mg, 80%) as an inseparable mixture of diastereoisomers (1:0.7).

LRMS (FAB⁺): 453 (M⁺ + H). HRMS (FAB⁺): calcd for C₂₂H₃₃N₂O₈: 453.2159 (M⁺ + H); found: 453.2237 (M⁺ + H).

Major diastereoisomer δ_{H} 1.25 (3H, t, $J = 7.1$ Hz, C2-OCH₂CH₃), 1.38 (3H, t, $J = 7.1$ Hz, -CO₂CH₂CH₃), 2.19 (3H, s, Ar-Me), 2.60 (1H, d, $J = 17.3$ Hz, C5-H), 2.76 (3H, s, *N*-CH₃), 2.81 (1H, dd, $J = 13.9, 5.9$ Hz, C2-CH₂), 3.34 (1H, dd, $J = 13.9, 3.6$ Hz, C2-CH₂), 3.39 (1H, d, $J = 17.3$ Hz, C5-H), 3.50 (2H, q, $J = 7.1$ Hz, C2-OCH₂CH₃), 3.62, 3.79, 3.80 (each 3H, s, Ar-OCH₃), 4.2-4.3 (2H, m, -CO₂CH₂CH₃), 4.58 (1H, dd, $J = 5.9, 3.6$ Hz, C2-H), 5.89 (1H, s, C2-H), 6.76 (1H, s, C6-H).

Minor diastereoisomer δ_{H} 1.28 (3H, t, $J = 7.1$ Hz, C2-OCH₂CH₃), 1.36 (3H, t, $J = 7.1$ Hz, -CO₂CH₂CH₃), 2.19 (3H, s, Ar-Me), 2.73 (1H, d, $J = 17.3$ Hz, C5-H), around 2.76 (1H, C2-CH₂, overlapped), 2.77 (3H, s, *N*-CH₃), 3.15 (1H, dd, $J = 13.7, 5.9$ Hz, C2-CH₂), 3.43 (1H, d, $J = 17.3$ Hz, C5-H), 3.7-3.9 (2H, m, C2-OCH₂CH₃), 3.63, 3.79, 3.80 (each 3H, s, Ar-OCH₃), 4.2-4.3 (1H, m, C2-H), 4.3-4.4 (2H, m, -CO₂CH₂CH₃), 5.95 (1H, s, C2-H), 6.70 (1H, s, C6-H)

Cyclization of compound **8** using acid (General procedure)

BF₃OEt₂ or *p*-toluenesulfonic acid was added to a solution of **8** in TFA, CH₂Cl₂ or ClCH₂CH₂Cl and the reaction mixture was heated under reflux. The reaction mixture was diluted with water, made alkaline with saturated aqueous NaHCO₃ solution, and extracted with CHCl₃ (20 mL x 3). The combined extracts were washed with brine (20 mL), dried, and concentrated *in vacuo* and the residue was subjected to column chromatography using gradient elution with EtOAc-*n*-hexane to give **7c** and **9**.

Spiro compound (**9**): pale yellow amorphous powder. IR ν_{max} (KBr) 3468, 2929, 1749, 1666 cm⁻¹. δ_{H} 1.09 (3H, t, $J = 7.1$ Hz, -CO₂CH₂CH₃), 2.01 (3H, s, C3-CH₃), 2.31 (1H, dd, $J = 12.6, 6.4$ Hz, C3'-H), 2.74 (1H, dd, $J = 12.6, 11.2$ Hz, C3'-H), 3.06 (3H, s, *N*-CH₃), 3.88 (1H, d, $J = 16.7$ Hz, C6'-H), 3.63, 3.99 (each 3H, s, Ar-OCH₃), 4.01-4.17 (2H, m, -CO₂CH₂CH₃), 4.36 (1H, d, $J = 16.7$ Hz, C6'-H), 4.70 (1H, dd, $J = 11.2, 6.4$ Hz, C3a'-H), 4.82 (1H, s, C1'-H), 5.53 (1H, s, C6-H). δ_{C} 10.5 (q, C3-CH₃), 14.1 (q, -CO₂CH₂CH₃), 33.8 (q, *N*-Me), 39.9 (t, C-3'), 49.8 (s, C-1), 53.3 (t, C-6'), 55.2 (q, C5-OCH₃), 58.5 (d, C-3a'), 61.7 (t, -CO₂CH₂CH₃), 62.2 (q, C2-OCH₃), 65.2 (d, C-1'), 108.3 (d, C-6), 121.1 (s, C-3), 150.3 (s, C-5), 162.2 (s, C-7'), 165.8 (s, C-4'), 167.2 (s, CO₂Et), 168.1 (s, C-2), 182.0 (s, C-4). LRMS (FAB⁺): 393 (M⁺ + H). HRMS (FAB⁺): calcd for C₁₉H₂₄N₂O₇: 393.1584 (M⁺ + H); found: 393.1660 (M⁺ + H).

Preparation of **7c** (One-pot procedure)

Trimethylsilyl chloride (26.9 μ L, 0.21 mmol) was added to a solution of **6** (33.9 mg, 0.11 mmol) in

ClCH₂CH₂Cl (1 mL) and triethylamine (29.3 μ L, 0.21 mmol), and the reaction mixture was stirred at rt for 2 h. A solution of ethyl diethoxyacetate (37.7 μ L, 0.21 mmol) in ClCH₂CH₂Cl (1 mL), followed by TMSOTf (190.5 μ L, 1.05 mmol), was added dropwise respectively over 5 min, and the reaction mixture was stirred at rt for 16 h. TLC monitoring at this stage revealed no trace of starting material **6**. Then, the reaction mixture was warmed to 100°C and heated under reflux for 4 h. The reaction mixture was diluted with water, made alkaline with saturated aqueous NaHCO₃ solution, and extracted with CHCl₃ (30 mL x 3). The combined extracts were washed with brine (30 mL), dried, and concentrated *in vacuo* and the residue was subjected to column chromatography with EtOAc-*n*-hexane (9:1) to give **7c** (39.8 mg, 93%) as a solid, recrystallization of which from EtOAc afforded **7c** as colorless prisms.

mp 168-170°C. IR_{vmax} (KBr) 2941, 1741, 1674 cm⁻¹. δ _H 1.27 (3H, t, *J* = 7.2 Hz, -O-CH₂CH₃), 2.20 (3H, s, Ar-CH₃), 3.02 (3H, s, *N*-CH₃), 3.03 (1H, dd, *J* = 16.8, 9.8 Hz, C11-H), 3.32 (1H, dd, *J* = 16.8, 5.1 Hz, C11-H), 3.71, 3.78, 3.87 (each 3H, s, Ar-OCH₃), 4.02 (1H, d, *J* = 17.5 Hz, C3-H), 4.14 (1H, d, *J* = 17.5 Hz, C3-H), 4.21 (2H, q, *J* = 7.2 Hz, -O-CH₂CH₃), 4.47 (1H, dd, *J* = 9.8, 5.1 Hz, C11a-H), 6.45 (1H, s, C6-H). δ _C 9.4 (q, Ar-CH₃), 14.1 (q, -CO₂CH₂CH₃), 26.7 (t, C11), 33.6 (q, *N*-CH₃), 51.3 (d, C6), 51.6 (t, C3), 53.4 (d, C11a), 59.9, 60.0, 60.2 (each q, Ar-OCH₃), 62.0 (t, -CO₂CH₂CH₃), 121.6 (s), 122.2 (s), 125.8 (s), 146.5 (s), 150.1 (s), 152.1 (s), 162.5 (s), 165.5 (s), 169.1 (s). EI-MS *m/z* (%): 406 (M⁺, 13), 334 (19), 333 (100). Anal. Calcd for C₂₀H₂₆N₂O₇: C, 59.10; H, 6.45; N, 6.89. Found: C, 58.98; H, 6.39; N, 6.87.

X-Ray crystallographic analysis of 7c All measurements were performed on a Rigaku AFC7S diffractometer with graphite-monochromated CuK α radiation (λ =1.54178 Å). Crystal data: Colorless prismatic crystal, monoclinic, C₂₀H₂₆N₂O₇ (*M*_r=406.43), space group P2₁/c with *a*=11.647(5) Å, *b*=9.299(7) Å, *c*=19.16(2) Å, β =102.06(4)°, *V*=2029(2) Å³, *Z*=4, and *D*_{calcd}=1.330 g/cm³. The structure was solved by direct methods (SHELXS-97¹⁸) and expanded using Fourier techniques (DIRDIF94¹⁹). Non-hydrogen atoms were refined anisotropically. Hydrogen atoms were included in calculated positions but were not refined. The final cycle of full-matrix least-squares refinement was based on 3691 unique reflections ($2\theta < 136.11^\circ$) and 262 variable parameters and converged with unweighted and weighted agreement factors of *R*=0.071, *R*_w=0.179, and *R*₁=0.043 for *I* > 2.0 σ (*I*) data. CCDC-No. 687,438 contains supplementary crystallographic data for this paper. These data can be obtained free of charge *via* www.ccdc.cam.ac.uk/data_request/cif.

(6*S, 11*aR**)-6-Hydroxymethyl-7,8,10-trimethoxy-2,9-dimethyl-3,6,11,11a-tetrahydro-2*H*-pyrazino[1,2-*b*]-isoquinoline-1,4-dione (10)** A solution of lithium hydroxide monohydrate (45.0 mg, 1.07 mmol) in water (1 mL) was added to a solution of **7c** (363 mg, 0.89 mmol) in THF (3 mL) and MeOH (1 mL), and the reaction mixture was stirred at rt for 22 h. The reaction mixture was poured into aqueous 1 N HCl (10 mL) at 0°C and extracted with CHCl₃ (100 mL x 3). The combined extracts were washed with brine (100

mL), dried, and concentrated *in vacuo* to give a carboxylic acid (310.7 mg), which was used in the next step without further purification.

Ethyl chloroformate (102.5 μL , 1.07 mmol) was added to a stirred solution of the above residue and triethylamine (143.2 μL , 1.03 mmol) in THF (16 mL), and the reaction mixture was stirred at -5°C for 2 h. After filtration of the mixture, the filter cake was carefully washed with THF. A suspension of sodium borohydride (75.4 mg, 2.00 mmol) in water (0.5 mL) was added to the combined filtrates at 0°C , and the mixture was stirred at the same temperature for 2 h. Saturated aqueous ammonium chloride solution was added to the reaction mixture and the mixture was extracted with CHCl_3 (200 mL \times 3). The combined extracts were washed with brine (200 mL), dried, and concentrated *in vacuo* to give a pale yellow solid (300.9 mg). Chromatography on silica gel column with EtOAc afforded **11** (56.7 mg, 17%) as a pale yellow syrup. Further elution with CHCl_3 -MeOH (20:1) gave **10** (168.8 mg, 52%) as a colorless solid, recrystallization of which from Et_2O gave pure **10** as colorless prisms.

10: mp $214\text{--}216^{\circ}\text{C}$. IR $_{\text{vmax}}$ (KBr) 3383, 2937, 1662, 1643 cm^{-1} . δ_{H} 2.19 (3H, s, Ar- CH_3), 2.75 (1H, dd, $J = 16.9, 12.1$ Hz, C11-H), 3.04 (3H, s, $N\text{-CH}_3$), 3.51 (1H, dd, $J = 16.9, 4.5$ Hz, C11-H), 3.67 (3H, s, Ar- OCH_3), 3.77 (1H, dd, $J = 11.2, 8.8$ Hz, C12-H), 3.79 (3H, s, Ar- OCH_3), 3.90 (3H, s, Ar- OCH_3), 4.08 (1H, dd, $J = 11.2, 3.9$ Hz, C12-H), 4.09 (2H, s, C3-H), 4.51 (1H, dd, $J = 12.1, 4.5$ Hz, C11a-H), 5.93 (1H, dd, $J = 8.8, 3.9$ Hz, C6-H). δ_{C} 9.5 (q, Ar- CH_3), 28.5 (t, C11), 33.5 (q, $N\text{-CH}_3$), 51.3 (d, C11a), 51.5 (t, C3), 52.0 (d, C6), 60.1 (q \times 2, Ar- OCH_3), 60.5 (q, Ar- OCH_3), 63.8 (t, C12), 121.8 (s, C6a), 122.8 (s, C10a), 125.1 (s, C9), 145.9 (s, C7), 150.1 (s, C8), 152.2 (s, C10), 162.5 (s, C4), 165.2 (s, C1). EI-MS m/z (%): 364 (M^+ , 4), 333 (100), 305 (14), 234 (13), 204 (10). HRMS (EI^+): calcd for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_6$: 364.1634 (M^+), found: 364.1636 (M^+). Anal. Calcd for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_5$: C, 59.33; H, 6.64; N, 7.69. Found: C, 59.16; H, 6.74; N, 7.67.

(6R*, 11aR*)-6-Hydroxymethyl-7,8,10-trimethoxy-2,9-dimethyl-3,6,11,11a-tetrahydro-2H-pyrazino[1,2-b]-isoquinoline-1,4-dione (11): IR $_{\text{vmax}}$ (KBr) 3433, 2941, 1664 cm^{-1} . δ_{H} 2.21 (3H, s, Ar- CH_3), 2.78 (1H, dd, $J = 15.7, 12.8$ Hz, C11-H), 3.07 (3H, s, $N\text{-CH}_3$), 3.5-3.8 (2H, m, C12-H), 3.71 (3H, s, Ar- OCH_3), 3.77 (1H, dd, $J = 15.7, 3.9$ Hz, C11-H), 3.80 (3H, s, Ar- OCH_3), 3.88 (1H, dd, $J = 12.8, 3.9$ Hz, C11a-H), 3.90 (3H, s, Ar- OCH_3), 3.97 (1H, d, $J = 16.7$ Hz, C3-H), 4.14 (1H, dd, $J = 16.7, 1.3$ Hz, C3-H), 5.83 (1H, dd, $J = 6.9, 4.4$ Hz, C6-H). δ_{C} 9.4 (q, Ar- CH_3), 24.1 (t, C11), 33.8 (q, $N\text{-CH}_3$), 52.5 (t, C3), 52.8 (d, C6), 55.3 (d, C11a), 60.0 (q, Ar- OCH_3), 60.7 (q, Ar- OCH_3), 61.1 (q, Ar- OCH_3), 67.3 (t, C12), 122.9 (s), 124.1 (s), 125.6 (s), 146.0 (s), 150.4 (s), 151.6 (s), 166.5 (s), 167.4 (s). EI-MS m/z (%): 364 (M^+ , 3), 347 (17), 333 (100), 305 (14), 234 (14), 204 (11). HRMS (EI^+): calcd for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_6$: 364.1634 (M^+), found: 364.1629 (M^+).

(6S*, 11aR*)-6-Iodomethyl-7,8,10-trimethoxy-2,9-dimethyl-3,6,11,11a-tetrahydro-2H-pyrazino[1,2-b]-isoquinoline-1,4-dione (12) Methyltriphenoxyphosphonium iodide (69.3 mg, 0.15 mmol) was added to

a solution of **10** (27.9 mg, 0.08 mmol) in dry DMF (1.5 mL) at 0°C, and the reaction mixture was stirred for 2.5 h at 0°C. The reaction mixture was diluted with Et₂O (15 mL) and H₂O (15 mL). The phases were allowed to separate, and the aqueous phase was extracted with Et₂O (15 mL x 3). The combined extracts were washed with brine (15 mL), dried, and concentrated *in vacuo* to give a residue, which was purified by column chromatography with CHCl₃ to give **12** (31.7 mg, 87%) as colorless amorphous powder.

IR_{vmax} (KBr) 3452, 2933, 1664 cm⁻¹. δ_H 2.18 (3H, s, Ar-CH₃), 2.64 (1H, dd, *J* = 17.1, 12.4 Hz, C11-H), 3.07 (3H, s, *N*-CH₃), 3.30 (1H, t, *J* = 11.3 Hz, C12-H), 3.42 (1H, dd, *J* = 17.1, 4.5 Hz, C11-H), 3.66 (3H, s, Ar-OCH₃), 3.79 (3H, s, Ar-OCH₃), 3.82 (1H, dd, *J* = 11.3, 3.8 Hz, C12-H), 3.92 (3H, s, Ar-OCH₃), 4.06 (1H, dd, *J* = 17.8, 0.7 Hz, C3-H), 4.16 (1H, d, *J* = 17.8 Hz, C3-H), 4.31 (1H, dd, *J* = 12.4, 4.5 Hz, C11a-H), 5.99 (1H, dd, *J* = 11.3, 3.8 Hz, C6-H). δ_C 5.8 (t, C12), 9.6 (q, Ar-CH₃), 28.6 (t, C11), 33.6 (q, *N*-CH₃), 49.0 (d, C11a), 51.1 (d, C6), 51.4 (t, C3), 60.0 (q, Ar-OCH₃), 60.1 (q, Ar-OCH₃), 60.6 (q, Ar-OCH₃), 120.8 (s), 124.9 (s), 125.6 (s), 146.0 (s), 150.2 (s), 152.2 (s), 161.6 (s), 165.20 (s). EI-MS *m/z* (%): 474 (M⁺, 26), 347 (78), 333 (100), 305 (15), 234 (10). HRMS (EI⁺): calcd for C₁₈H₂₃IN₂O₅: 474.0652 (M⁺), found: 474.0651 (M⁺).

(6*S**, 11*aR**)-7,8,10-Trimethoxy-2,6,9-trimethyl-3,6,11,11*a*-tetrahydro-2*H*-pyrazino[1,2-*b*]isoquinoline-1,4-dione (**7b**) A solution of **12** (10.5 mg, 0.022 mmol) in MeOH (1.0 mL) was hydrogenated over 10% Pd/C (2.4 mg) in the presence of sodium acetate (3.0 mg, 0.022 mmol) for 4 h at rt. The catalyst was removed by filtration and washed with MeOH and CHCl₃. The combined filtrates were concentrated *in vacuo* and the crude material was purified by column chromatography with MeOH-CHCl₃ (1:100) to give **7b** (7.7 mg, 100%) as a colorless solid, whose spectra were identical with those of an authentic sample described above.

ACKNOWLEDGEMENTS

This research was partially supported by the Japan Society for the Promotion of Science (JSPS) AA Scientific Platform Program. We are grateful to Dr. Kazuhiko Takatori (Meiji Pharmaceutical University) for X-ray structure analysis of single crystals.

REFERENCES

1. J. D. Scott and R. M. Williams, *Chem. Rev.*, 2002, **102**, 1669.
2. a) E. J. Martinez, T. Owa, S. L. Schreiber, and E. J. Corey, *Proc. Natl. Acad. Sci., USA*, 1999, **96**, 3496. b) M. –H. D. Cordonnier, C. Gajate, O. Olmea, W. Laine, J. de la Iglesia-Vicente, C. Perez, C. Cuevas, G. Otero, I. Manzanares, C. Bailly, and F. Mollinedo, *Chem. Biol.*, 2005, **12**, 1201.
3. B. S. Davidson, *Tetrahedron Lett.*, 1992, **33**, 3721.

4. a) G. R. Pettit, J. C. Knight, J. C. Collins, D. L. Herald, R. K. Pettit, M. R. Boyd, and V. G. Young, *J. Nat. Prod.*, 2000, **63**, 793. b) P. S. Parameswaran, G. C. Naik, S. Y. Kamat, and B. N. Pramanik, *Indian J. Chem., Sect. B*, 1998, **37**, 1258. c) N. Saito, H. Sakai, K. Suwanborirux, S. Pummangura, and A. Kubo, *Heterocycles*, 2001, **55**, 21.
5. a) P. Magnus and K. S. Matthews, *J. Am. Chem. Soc.*, 2005, **127**, 12476. b) J. W. Lane, Y. Chen, and R. M. Williams, *J. Am. Chem. Soc.*, 2005, **127**, 12684.
6. a) C. Chan, R. Heid, S. Zheng, J. Guo, B. Zhou, T. Furuuchi, and S. J. Danishefsky, *J. Am. Chem. Soc.*, 2005, **127**, 4596. b) G. Vincent and R. M. Williams, *Angew. Chem. Int. Ed.*, 2007, **46**, 1517. c) X. Chen and J. Zhu, *Angew. Chem. Int. Ed.*, 2007, **46**, 3962.
7. For simplicity, natural products situation numbering is used in this paper except the Experimental section.
8. A. Kubo, N. Saito, H. Yamato, R. Yamauchi, K. Hiruma, and S. Inoue, *Chem. Pharm. Bull.*, 1988, **36**, 2607.
9. a) C. W. Ong, Y. A. Chang, J.-Y. Wu, and C.-C. Cheng, *Tetrahedron*, 2003, **59**, 8245. b) C. W. Ong and H. C. Lee, *Aust. J. Chem.*, 1990, **43**, 773.
10. Reaction of **6** with ethyl glyoxylate and benzenetriazole in refluxing toluene in the presence of *p*-TsOH, followed by Friedel-Crafts-type reaction using Katritzky et al.'s methodology¹¹ also failed, and only starting material **6** was recovered.
11. a) O. Koepler, S. Laschat, A. Baro, P. Ficsher, B. Miehllich, M. Hotfilder, and C. le Viseur, *Eur. J. Org. Chem.*, 2004, 3611. b) A. R. Katritzky, J. Cobo-Domingo, B. Yang, and P. J. Steel, *Tetrahedron: Asymmetry*, 1999, **10**, 255.
12. a) J. F. González, E. de la Cuesta, and C. Avendaño, *Tetrahedron Lett.*, 2003, **44**, 4395. b) J. F. González, E. de la Cuesta, and C. Avendaño, *Tetrahedron*, 2004, **60**, 6319. c) J. F. González, L. Salazar, E. de la Cuesta, and C. Avendaño, *Tetrahedron*, 2005, **61**, 7447.
13. The stereochemistry of **9** has not been determined so far.
14. C. H. Heathcock, M. M. Hansen, R. B. Ruggeri, and J. C. Kath, *J. Org. Chem.*, 1992, **57**, 2544.
15. K. Soai and A. Ookawa, *J. Org. Chem.*, 1986, **51**, 4000.
16. T. Eguchi, M. Fukuda, Y. Toyooka, and K. Kakinuma, *Tetrahedron*, 1998, **54**, 705.
17. L. A. Dakin and J. S. Panek, *Org. Lett.*, 2003, **5**, 3995.
18. G. M. Shelxs, (1997). Program for the Solution of Crystal Structures. University of Göttingen, Germany.
19. P. T. Beurskens, G. Admiraal, G. Beurskens, W. P. Bosman, R. Gelder, R. Israel, and J. M. M. Smits, *The DIRDIF-94 program system*, Technical Report of the Crystallography Laboratory; University of Nijmegen: The Netherlands, 1994.